Vaccinex, Inc. (NASDAQ:VCNX – Get Free Report)’s share price traded down 16.4% during trading on Tuesday . The stock traded as low as $0.80 and last traded at $0.8357. 1,348 shares changed hands during trading, a decline of 64% from the average session volume of 3,696 shares. The stock had previously closed at $1.00.
Vaccinex Price Performance
The stock has a market capitalization of $2.01 million, a P/E ratio of -0.02 and a beta of 1.10. The stock’s fifty day moving average is $1.02 and its 200-day moving average is $0.98.
About Vaccinex
Vaccinex, Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting oncology and neurodegenerative diseases. Headquartered in Rochester, New York, Vaccinex harnesses its proprietary human antibody platform to modulate the semaphorin 4D (SEMA4D) pathway, a mechanism implicated in tumor immune evasion and neuroinflammatory processes. Its lead asset, pepinemab (VX15/2503), is an investigational monoclonal antibody designed to bind and block SEMA4D, thereby promoting immune cell infiltration in tumors and supporting neural repair in degenerative disorders.
In oncology, Vaccinex has advanced pepinemab through Phase 2 trials in solid tumors and hematologic malignancies, exploring its potential to enhance the efficacy of established checkpoint inhibitors.
Further Reading
- Five stocks we like better than Vaccinex
- Coke’s $10B India IPO Plan Pops the Top on Hidden Value
- FedEx Unboxes Billions in Post-Spinoff Value
- Marvell’s AI Moment Raises a Bigger Question for Amazon and ServiceNow
- Palo Alto Networks Accelerates Growth 31% on AI Demand
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.
